AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
CETRORELIX
6 registrations across 4 African markets— 3 active
Markets with CETRORELIX
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| CETROTIDE 0,25MG POUDRE POUR SUSPENSION INJECTABLE BOITE DE 1 | 🇨🇮Côte d'Ivoire | MERCK SERONO EUROPE LIMITED | expired | Jan 2026 |
| CETROTIDE Pdre p.prep.injectable / 0.25 MG | 🇹🇳Tunisia | MERCK EUROPE B.V | expired | Jan 2022 |
| CETROTIDE Pdre p.prep.injectable / 3 MG | 🇹🇳Tunisia | MERCK SERONO EUROPE Limited UK | expired | May 2003 |
| CETROTIDE 0,25 mg | 🇿🇦South Africa | Merck (Pty) Ltd | active | Jan 1900 |
| CETRORELIX PARENTERAL
ORDINARY
COMBINATION
PACK VIALS | 🇺🇬Uganda | MERCK (PTY) LTD | active | — |
| CETRORELIX PARENTERAL
ORDINARY
COMBINATION
PACK VIALS | 🇺🇬Uganda | MERCK (PTY) LTD | active | — |
CETRORELIX in Africa — Regulatory Overview
CETRORELIX is registered across 4 African markets with 6 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Tunisia, Uganda, Côte d'Ivoire, South Africa. AfricaRegulatory refreshes this data daily from official government sources.
Of the 6 registrations, 3 (50%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.